Skip to main content
Premium Trial:

Request an Annual Quote

Ebola Test From J&J's Janssen Pharmaceutica Granted EUA by FDA

NEW YORK (GenomeWeb) – Johnson & Johnson affiliate Janssen Pharmaceutica announced today that its Ebola assay has been granted Emergency Use Authorization by the US Food and Drug Administration.

The Ebola Virus Triage Test, performed on the Biocartis Idylla platform, is a closed-tube real-time reverse transcription PCR test for qualitative detection of the virus in samples of whole blood. The automated test does not require cold chain storage, runs in 100 minutes, and requires minimal training to interpret results, Janssen noted in a statement. 

The EUA stipulates that testing is for individuals with signs and symptoms of Ebola combined with epidemiological risk factors. The 2014 outbreak in West Africa led to more than 11,000 deaths, with the US Centers for Disease Control and Prevention expecting additional cases to occur sporadically in the future.

The Ebola Virus Triage Test was jointly developed by Janssen's diagnostics division, Biocartis, and the Belgium Institute of Tropical Medicine. It has been in development since 2015, and is the twelfth Ebola assay to be granted EUA since the emergency was declared — nine of the 12 authorized tests are RT-PCR-based.

Janssen is also developing other tests in the infectious disease space for the fully automated, random-access Idylla platform, including ones for hepatitis C viral load and influenza surveillance. The firm's influenza A/B and RSV panel was CE-marked last year.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.